Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Novartis AG

Sanofi Genzyme’s Treatment For Pompe Disease On Track For EU Approval

EU reviewers have recommended marketing approval for two new medicines, but have turned down another product. 

Europe Drug Review

Pemaryze Wins Cost-Effectiveness Thumbs Up For Rare Bile Duct Cancer In England

Bavencio, Taltz, Cosentyx, and Opdivo plus Yervoy were this week also the subject of final recommendations from the health technology assessment body, NICE, on whether or not they should be used on the National Health Service for certain indications.

United Kingdom Health Technology Assessment

Arvinas, Pfizer Partner To Pursue Best-In-Class Breast Cancer Strategy

Pfizer agreed to pay up to $2.4bn to share development and commercialization costs for Arvinas’ estrogen receptor degrader, including in combination with Ibrance.

Deals Cancer

Novartis Not Nervous About SGLT2 Threat To Entresto

The company's pharma chief Marie-France Tschudin does not expect Entresto's "unique position" in heart failure to be threatened by SGLT2 inhibitors such as Jardiance and Farxiga, saying those drugs are add-ons that will be used predominantly in diabetes patients.

Cardiovascular Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Admune Therapeutics
    • Amblyotech, Inc.
    • Advanced Accelerator Applications SA (AAAP) (BioSynthema, Inc.)
    • Aspen Japan K.K.
    • Biocine
    • CELLforCURE SASU
    • Chiron Corporation
    • CIBA-GEIGY
    • Corthera Inc.
    • CoStim Pharmaceuticals Inc.
    • ESBATech AG
    • Fougera Pharmaceuticals, Inc.
    • Hexal AG
    • Lek Pharmaceuticals, Inc.
    • Matrix Pharmaceuticals
    • NeuTec Pharma
    • Novartis Groupe France S.A.
    • Novartis Pharmaceuticals
    • Novartis Oncology
    • Novogyne Pharmaceuticals (joint venture between Noven and Novartis)
    • PowerVision, Inc.
    • Protez Pharmaceuticals
    • Sandoz Pharmaceuticals (Ever Neuro Pharma GmbH
    • Ebewe Pharma)
    • Selexys Pharmaceuticals Corporation
    • Speedel Holding
    • Spinifex Pharmaceuticals Pty. Ltd.
    • Transcend Medical, Inc.
    • Encore Vision, Inc.
    • Ziarco Group Limited
    • AveXis, Inc.
    • BioLife Cell Bank, Inc.
    • Endocyte, Inc.
    • IFM Tre
    • Zyma SA
    • Annovation Biopharma, Inc.
    • Boxford Subsidiary
    • Curacyte Discovery GmbH
    • Incline Therapeutics, Inc.
    • ProFibrix B.V.
    • Rempex Pharmaceuticals, Inc.
    • Targanta Therapeutics Corporation
    • Tenaxis Medical
    • The Medicines Company
    • Novartis Gene Therapies
UsernamePublicRestriction

Register